Paper Details

  1. Home
  2. Paper Details

Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.

Author: MüllerThomas

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article highlights the potential of A2A adenosine receptor antagonism, particularly with the use of istradefylline, as a therapeutic approach for improving motor function in Parkinson's disease.
Paper Details　
Original Abstract of the Article :
Recent experimental and clinical research has shown that A2A adenosine receptor antagonism can bring about an improvement in the motor behavior of patients with Parkinson's disease. Istradefylline , a xanthine derivative, has the longest half-life of all the currently available A2A adenosine recepto...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/17425255.2013.795541

データ提供：米国国立医学図書館（NLM）

Suitability of the Adenosine Antagonist Istradefylline for the Treatment of Parkinson's Disease: Pharmacokinetic and Clinical Considerations

The desert of Parkinson's disease research is constantly searching for new and effective treatments to alleviate the debilitating symptoms of this neurodegenerative disorder. This study explores the potential of istradefylline, an adenosine antagonist, as a promising therapeutic agent for Parkinson's disease. The authors delve into the pharmacokinetic and clinical considerations surrounding istradefylline, examining its unique properties, such as its long half-life, ability to cross the blood-brain barrier, and high affinity for A2A adenosine receptors. This research sheds light on the potential benefits and challenges of istradefylline as a treatment option for Parkinson's disease.

A New Oasis in the Desert of Parkinson's Disease: The Potential of Istradefylline

This study explores the potential of istradefylline, an adenosine antagonist, as a promising therapeutic agent for Parkinson's disease. The authors' examination of its pharmacokinetic and clinical properties, including its long half-life, ability to cross the blood-brain barrier, and high affinity for A2A adenosine receptors, suggests that istradefylline may offer a valuable treatment option for this debilitating disorder.

Navigating the Desert of Parkinson's Disease: Istradefylline and its Potential Benefits

This study highlights the potential of istradefylline as a promising therapeutic agent for Parkinson's disease. The authors' analysis of its pharmacokinetic and clinical properties, including its long half-life, ability to cross the blood-brain barrier, and high affinity for A2A adenosine receptors, suggests that istradefylline may offer a valuable treatment option for this debilitating disorder.

Dr. Camel's Conclusion

This study explores the potential of istradefylline, an adenosine antagonist, as a promising therapeutic agent for Parkinson's disease. The authors' meticulous examination of its pharmacokinetic and clinical properties suggests that istradefylline may offer a valuable treatment option for this debilitating disorder. This research contributes to the ongoing search for effective therapies in the vast desert of Parkinson's disease research.
Date :
  1. Date Completed 2014-02-07
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

23642267

DOI: Digital Object Identifier

10.1517/17425255.2013.795541

Related Literature

Article Analysis
・Side Effects of istradefylline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.